DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival

View at publisher
Authors: Giorgia Chiodin, Dylan James Tatterton, Philip J. Rock, Luis Del Rio, Erin Snook, Sonya James, Patrick J. Duriez, Miriam Di Re, Martijn Verdoes, Stuart Lanham, Daniel James Hodson, Richard W. Burack
+1 more Francesco Forconi
Cited by: 1
References: 38

Abstract

ABSTRACT: The occupation of the surface immunoglobulin antigen-binding site by oligomannose-type glycans (sIg-Mann) is a tumor-specific posttranslational modification of classic follicular lymphoma (FL). SIg-Mann switches binding from antigen to dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), which is expressed on interfollicular macrophages and FL-associated follicular dendritic cells (FDCs). The interaction with DC-SIGN induces reorganization of sIg-Mann in wider and less dense clusters than anti-Ig, consistent with inefficient DC-SIGN-induced endocytosis and low-level intracellular signaling. However, ligand-specific cell clusters form between sIg-Mann-expressing lymphoma cells and DC-SIGN-expressing cells, raising the need to understand the functional consequences of the interaction of DC-SIGN with sIg-Mann on primary FL cells. This engagement induces adhesion of FL cells to vascular cell adhesion molecule 1 (VCAM-1) via B-cell receptor-proximal kinases and actin regulators in a fashion similar to anti-Ig but without initiating apoptosis in vitro. Instead, antibody blockade of sIg-Mann contact with DC-SIGN, expressed on FDC-derived YK6/SIGN cells, inhibits adhesion and survival of primary FL cells in vitro. These data highlight that the specific interaction with DC-SIGN induces FL cell adhesion to VCAM-1, likely allowing FL cell retention in the lymph node and FL cell survival. Adhesion and survival are inhibited by an anti-DC-SIGN blocking antibody, indicating a new early therapeutic approach against FL retention and survival in adaptive tumor-tissue niches.

Fields of Study & Subjects

Immunotherapy and Immune Responses Cell Adhesion Molecules Research HER2/EGFR in Cancer Research

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
18
Pages
2089–2097
Publication date
20 January 2026
Language
EN